ReviewBreathe (Sheffield, England)2018
Is there room for further innovation in inhaled therapy for airways disease?
Review in Breathe (Sheffield, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of new digital technologies and telemedicine in pulmonary rehabilitation : Smart devices in the treatment of chronic respiratory diseases.Wiener klinische Wochenschrift · 2021Pooled it
- Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments.Drugs · 2025Review
- The effects of airway disease on the deposition of inhaled drugs.Expert opinion on drug delivery · 2024Review
- Pulmonary Diseases in Older Patients: Understanding and Addressing the Challenges.Geriatrics (Basel, Switzerland) · 2024Article
- Reducing carbon footprint by switching to reusable soft-mist inhalers.ERJ open research · 2023Article
- COPD Patients' Behaviour When Involved in the Choice of Inhaler Device.Healthcare (Basel, Switzerland) · 2023Article
- Inhaler Adherence in COPD: A Crucial Step Towards the Correct Treatment.International journal of chronic obstructive pulmonary disease · 2023Review
- Salbutamol in the Management of Asthma: A Review.International journal of molecular sciences · 2022Review
- Impact of Sex on Proper Use of Inhaler Devices in Asthma and COPD: A Systematic Review and Meta-Analysis.Pharmaceutics · 2022Review
- The Current and Future Role of Technology in Respiratory Care.Pulmonary therapy · 2022Review
- A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases.Journal of nanobiotechnology · 2022Review
- Article
- The future of inhalation therapy in chronic obstructive pulmonary disease.Current research in pharmacology and drug discovery · 2022Review
- Pulmonary Delivery of Biological Drugs.Pharmaceutics · 2020Review
- Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020Review
- Asthma management with breath-triggered inhalers: innovation through design.Asthma research and practice · 2020Review
- Nebulized Therapies in COPD: Past, Present, and the Future.International journal of chronic obstructive pulmonary disease · 2020Review
- Biological Obstacles for IdentifyingPharmaceutics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled medication is the cornerstone in the treatment of patients across a spectrum of respiratory diseases including asthma and chronic obstructive pulmonary disease. The benefits of inhaled therapy have long been recognised but the most important innovations have occurred over the past 60 years, beginning with the invention of the pressurised metered dose inhaler. However, despite over 230 different device and drug combinations currently being available, disease control is far from perfect. Here we look at how innovation in inhaler design may improve treatments for respiratory diseases and how new formulations may lead to treatments for diseases beyond the lungs. We look at the three main areas where innovation in inhaled therapy is most likely to occur: 1) device engineering and design; 2) chemistry and formulations; and 3) digital technology associated with inhalers. Inhaler design has improved significantly but considerable challenges still remain in order to continually innovate and improve targeted drug delivery to the lungs. Healthcare professionals want see innovations that motivate their patients to achieve their goal of improving their health, through better adherence to treatment. Patients want devices that are easy to use and to see that their efforts are rewarded by improvements in their condition. KEY POINTS: The dictionary definition of innovation is the introduction of new things, ideas or ways of doing something. We show how this definition can be applied to inhaled therapy.We take a look at the past to see what drove innovation in inhaler design and how this has led to the current devices.We look at the current drivers of innovation in engineering, chemistry and digital technology and predict how this may translate to new devices.Can innovation help the healthcare professional manage their patients better?What does the patient expect from innovation in their device? EDUCATIONAL
aimsTo understand the importance of inhaled medication in the treatment of lung diseases.To understand how innovation has helped advance some of the devices patients use today from basic and inefficient designs.To understand the obstacles that prevent patients from receiving optimal treatment from their inhalers.To understand how innovation in inhaler design can lead to improved treatment for patients and widen the range of diseases that can be treated
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.